BRAF and melanoma: Hyperphosphorylation of the EGFR receptor has been previously reported in BRAF class 3–mutated NSCLC and colorectal cancer (CRC) cells, but not in malignant melanoma cells.6 Consistently, EGFR inhibition with erlotinib or cetuximab was effective in BRAF class 3–mutated NSCLC and CRC cell lines.